Sequential azacitidine plus lenalidomide in previously treated elderly patients with acute myeloid leukemia and higher risk myelodysplastic syndrome

References

• Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Cancer J Clin 2007; 57: 43–66.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Burnett AK, Wheatley K, et al. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood 2001; 98:1302–1311.
   PubMed Web of Science ®Google Scholar
• Estey E, Dohner H. Acute myeloid leukaemia. Lancet 2006; 368: 1894–1907.
   PubMed Web of Science ®Google Scholar
• Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009; 113: 4179–4187.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.
   PubMed Web of Science ®Google Scholar
• Krug U, Rollig C, Koschmieder A, et al. Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a web-based application for prediction of outcomes. Lancet 2010; 376: 2000–2008.
   PubMed Web of Science ®Google Scholar
• Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 1999; 94: 1086–1099.
   PubMed Web of Science ®Google Scholar
• Mohan SR, Fu A, Tiu RV, et al. Prior therapy with DNA Methyltransferase Inhibitors (DNMTI) predicts for lower remission rates and worse survival in Secondary Acute Myeloid Leukemia Patients (sAML) receiving remission induction therapy. Blood 2010; 116: 4033.
   Google Scholar
• Jabbour E, Garcia-Manero G, Batty N, et al. Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 2010; 116: 3830–3834.
   PubMed Web of Science ®Google Scholar
• Bello C, Yu D, Komrokji RS, et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011; 117: 1463–1469.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Zehnder J, Coutre S, et al. Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia. Haematologica 2013; 98: 591–596.
   PubMed Web of Science ®Google Scholar
• Ramsingh G, Westervelt P, Cashen AF, et al. A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML. Leukemia 2013; 27: 725–728.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, Tiu RV, Komrokji R, et al. Phase 2 study of the lenalidomide and azacitidine combination in patients with higher-risk myelodysplastic syndromes. Blood 2012; 120: 4945–4951.
   PubMed Web of Science ®Google Scholar
• Lancet JE, Komrokji RS, Yu D, et al. A phase 1 study of sequential idarubicin + cytarabine, followed by lenalidomide, in patients with previously untreated Acute Myeloid Leukemia (AML). Blood 2011; 118: 2600.
   Google Scholar
• Hickey CJ, Schwind S, Radomska HS, et al. Lenalidomide-mediated enhanced translation of C/EBPalpha-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia. Blood 2013; 121: 159–169.
   PubMed Web of Science ®Google Scholar
• Bogenberger JM, Kornblau SM, Pierceall WE, et al. BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies. Leukemia 2014; 28: 1657–1665.
   PubMed Web of Science ®Google Scholar
• Pollyea DA, Kohrt HE, Gallegos L, et al. Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia 2012; 26: 893–901.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006; 108: 419–425.
   PubMed Web of Science ®Google Scholar
• Pierceall WE, Lena RJ, Medeiros BC, et al. Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia. Leukemia Res 2014; 38: 564–568.
   PubMed Web of Science ®Google Scholar
• Pierceall WE, Kornblau SM, Carlson NE, et al. BH3 profiling discriminates response to cytarabine-based treatment of acute myelogenous leukemia. Mol Cancer Therapeut 2013; 12: 2940–2949.
   PubMed Web of Science ®Google Scholar
• Sekeres MA, O'Keefe C, List AF, et al. Demonstration of additional benefit in adding lenalidomide to azacitidine in patients with higher-risk myelodysplastic syndromes. Am J Hematol 2011; 86: 102–103.
   PubMed Web of Science ®Google Scholar
• Prebet T, Gore SD, Thepot S, et al. Outcome of acute myeloid leukaemia following myelodysplastic syndrome after azacitidine treatment failure. Br J Haematol 2012; 157: 764–766.
   PubMed Web of Science ®Google Scholar
• Jabbour E, Ghanem H, Huang X, et al. Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis. Clin Lymphoma Myeloma Leuk 2014; 14: 93–97.
   PubMed Web of Science ®Google Scholar
• Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 2011; 29: 3322–3327.
   PubMed Web of Science ®Google Scholar
• Lim SH, McMahan J, Zhang J, et al. A phase II study of low dose intravenous clofarabine for elderly patients with myelodysplastic syndrome who have failed 5-azacytidine. Leuk Lymphoma 2010; 51: 2258–2261.
   PubMed Web of Science ®Google Scholar
• Braun T, Raffoux E, Prebet T, et al. Low-dose clofarabine has significant activity in high-risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) failure: interim results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325). Blood 2011; 118: 609.
   Google Scholar
• Faderl S, Garcia-Manero G, Jabbour E, et al. A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome. Cancer 2012; 118: 722–728.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Roboz GJ, Rizzieri DA, et al. Results From the dose escalation phase of a randomized phase 1-2 First-in-Human (FIH) Study of SGI-110, a novel low volume stable Subcutaneous (SQ) Second Generation Hypomethylating Agent (HMA) in patients with Relapsed/Refractory MDS and AML. Blood 2012; 120: 414.
   Google Scholar
• Prebet T, Braun T, Beyne-Rauzy O, et al. Final Report of GFM-VOR2007 Study: a Phase I/II study of vorinostat and Low Dose Cytarabine (LDAC) for MDS patients with Azacitidine (AZA) Failure. Blood 2012; 120: 3825.
   Google Scholar
• Kadia TM, Jabbour E, Kantarjian H. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 2011; 38: 682–692.
   PubMed Web of Science ®Google Scholar
• Saunthararajah Y. Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program 2013; 2013: 511–521.
   PubMed Web of Science ®Google Scholar
• Qin T, Jelinek J, Si J, et al. Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines. Blood 2009; 113: 659–667.
   PubMed Web of Science ®Google Scholar
• Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147–1152.
   PubMed Web of Science ®Google Scholar
• Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 2014; 28: 78–87.
   PubMed Web of Science ®Google Scholar
• Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 2014; 124: 2705–2712.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Ding L, et al. Clonal architecture of secondary acute myeloid leukemia. N Engl J Med 2012; 366: 1090–1098.
   PubMed Web of Science ®Google Scholar
• Walter MJ, Shen D, Shao J, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia 2013; 27: 1275–1282.
   PubMed Web of Science ®Google Scholar